BioNTech SE宣布,在接下来五年内,预计将从处于晚期开发阶段的临床试验中发布至少17项数据成果。在肿瘤治疗领域,该公司计划于2026年启动另外6项三期临床试验。若临床试验数据呈现积极结果,BioNTech有望在2030年前发展成为拥有多款肿瘤产品的企业。
BioNTech SE宣布,在接下来五年内,预计将从处于晚期开发阶段的临床试验中发布至少17项数据成果。在肿瘤治疗领域,该公司计划于2026年启动另外6项三期临床试验。若临床试验数据呈现积极结果,BioNTech有望在2030年前发展成为拥有多款肿瘤产品的企业。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.